{
    "clinical_study": {
        "@rank": "161340", 
        "arm_group": {
            "arm_group_label": "Entecavir prophylaxis", 
            "arm_group_type": "Experimental", 
            "description": "Participants will initiate entecavir 0.5 mg/day orally on day 1 of the first course of immunochemotherapy and/or chemotherapy, and will be continued until 12 months after completion of the immunochemotherapy and/or chemotherapy."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to identify the effect of prophylactic entecavir in HBsAg\n      Positive lymphoma patients treated with rituximab-based immunochemotherapy."
        }, 
        "brief_title": "Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy", 
        "condition": "Hepatitis B", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  treatment-naive patients with B-cell lymphoma\n\n          -  HBsAg positive at baseline\n\n          -  treated with rituximab-based immunochemotherapy\n\n          -  life expectancy of more than 3 months\n\n        Exclusion Criteria:\n\n          -  younger than 18 years old\n\n          -  HBsAg negative at baseline\n\n          -  pregnant or lactating women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01768195", 
            "org_study_id": "PKU-2012111304"
        }, 
        "intervention": {
            "arm_group_label": "Entecavir prophylaxis", 
            "description": "Entecavir 0.5mg daily from day 1 of immunochemotherapy and/or chemotherapy to 12 months after completing immunochemotherapy and/or chemotherapy.\nIn patients with low load of hepatitis B virus DNA(\u22642000 IU/ml), rituximab will be administrated at the beginning of entecavir prophylaxis. And in patients with high load of hepatitis B virus DNA(>2000 IU/ml), rituximab will be administrated when hepatitis B virus DNA decreased to the level of 2000 IU/ml after entecavir prophylaxis.", 
            "intervention_name": "Entecavir prophylaxis", 
            "intervention_type": "Drug", 
            "other_name": "Baraclude"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Rituximab", 
                "Entecavir"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Lymphoma", 
            "Hepatitis B Virus", 
            "Therapeutic Uses", 
            "Antiviral Agents", 
            "rituximab"
        ], 
        "lastchanged_date": "January 12, 2013", 
        "location": [
            {
                "contact": {
                    "email": "zj@bjcancer.org", 
                    "last_name": "Jun Zhu"
                }, 
                "contact_backup": {
                    "email": "songyuqin622@sina.com", 
                    "last_name": "Yuqin Song"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100142"
                    }, 
                    "name": "Peking University Cancer Hospital & Institute"
                }, 
                "investigator": {
                    "last_name": "Jun Zhu", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Hanyun Ren"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing"
                    }, 
                    "name": "Peking University First Hospital"
                }, 
                "investigator": {
                    "last_name": "Hanyun Ren", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Xiaojun Huang"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing"
                    }, 
                    "name": "Peking University People's Hospital"
                }, 
                "investigator": {
                    "last_name": "Xiaojun Huang", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Xiaoyan Ke"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing"
                    }, 
                    "name": "Peking University Third Hospital"
                }, 
                "investigator": {
                    "last_name": "Xiaoyan Ke", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Daobin Zhou"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing"
                    }, 
                    "name": "Peking Union Medical College Hospital"
                }, 
                "investigator": {
                    "last_name": "Daobin Zhou", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Hui Liu"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing"
                    }, 
                    "name": "Beijing Hospital"
                }, 
                "investigator": {
                    "last_name": "Hui Liu", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Yuankai Shi"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing"
                    }, 
                    "name": "Cancer Institute & Hospital, Chinese Academy of Medical Sciences"
                }, 
                "investigator": {
                    "last_name": "Yuankai Shi", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Xiaoxiong Wu"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing"
                    }, 
                    "name": "First Hospital affiliated to General Hospital of the Chinese People's Liberation Army"
                }, 
                "investigator": {
                    "last_name": "Xiaoxiong Wu", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Weijing Zhang"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing"
                    }, 
                    "name": "307 Hospital of the Chinese People's Liberation Army"
                }, 
                "investigator": {
                    "last_name": "Weijing Zhang", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Liping Ye"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing"
                    }, 
                    "name": "309 Hospital of the Chinese People's Liberation Army"
                }, 
                "investigator": {
                    "last_name": "Liping Ye", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jingbo Wang"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing"
                    }, 
                    "name": "Aerospace Central Hospital"
                }, 
                "investigator": {
                    "last_name": "Jingbo Wang", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Mei Xue"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing"
                    }, 
                    "name": "Air Force General Hospital of the Chinese People's Liberation Army"
                }, 
                "investigator": {
                    "last_name": "Mei Xue", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Li Yu"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing"
                    }, 
                    "name": "General Hospital of Chinese People's Liberation Army"
                }, 
                "investigator": {
                    "last_name": "Li Yu", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "overall_contact": {
            "email": "zj@bjcancer.org", 
            "last_name": "Jun Zhu"
        }, 
        "overall_contact_backup": {
            "email": "songyuqin622@sina.com", 
            "last_name": "Yuqin Song"
        }, 
        "overall_official": {
            "affiliation": "Peking University Cancer Hospital & Institute", 
            "last_name": "Jun Zhu", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "the incidence of hepatitis B virus reactivation and hepatitis B virus reactivation related hepatitis", 
            "safety_issue": "Yes", 
            "time_frame": "from the beginning of immunochemotherapy and/or chemotherapy to 24 months after the last cycle of immunochemotherapy and/or chemotherapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01768195"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Peking University", 
            "investigator_full_name": "Jun Zhu", 
            "investigator_title": "Peking University Cancer Hospital & Institute", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "the incidence of hepatitis B virus virological response", 
                "safety_issue": "Yes", 
                "time_frame": "from the beginning of immunochemotherapy and/or chemotherapy to 24 months after the last cycle of immunochemotherapy and/or chemotherapy"
            }, 
            {
                "measure": "the incidence of hepatitis B virus serological response", 
                "safety_issue": "Yes", 
                "time_frame": "from the beginning of immunochemotherapy and/or chemotherapy to 24 months after the last cycle of immunochemotherapy and/or chemotherapy"
            }, 
            {
                "measure": "the incidence of hepatitis B virus maintained response", 
                "safety_issue": "Yes", 
                "time_frame": "from the beginning of immunochemotherapy and/or chemotherapy to 24 months after the last cycle of immunochemotherapy and/or chemotherapy"
            }, 
            {
                "measure": "the incidence of hepatitis B virus sustained response", 
                "safety_issue": "Yes", 
                "time_frame": "from the beginning of immunochemotherapy and/or chemotherapy to 24 months after the last cycle of immunochemotherapy and/or chemotherapy"
            }, 
            {
                "measure": "the incidence of hepatitis B virus relapse and relapse related hepatitis", 
                "safety_issue": "Yes", 
                "time_frame": "from the beginning of immunochemotherapy and/or chemotherapy to 24 months after the last cycle of immunochemotherapy and/or chemotherapy"
            }
        ], 
        "source": "Peking University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Peking University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}